L1CAM-specific CAR T-cells

L1CAM-specific CAR T-cells are autologous T lymphocytes genetically engineered to express a chimeric antigen receptor (CAR) targeting the L1 cell adhesion molecule (L1CAM, also known as CD171), a protein highly over-expressed on a variety of solid tumors such as neuroblastoma, ovarian, small cell neuroendocrine prostate, and other carcinomas, but largely absent from normal tissues[1][3][4]. These CAR T-cells recognize and bind to the CE7 epitope of L1CAM, initiating T cell-mediated cytotoxicity against L1CAM-expressing tumor cells. Second-generation constructs most commonly incorporate co-stimulatory domains such as CD28 or 4-1BB, and the CAR is typically delivered via lentiviral transduction[1][3]. This approach has been evaluated in preclinical models and early phase clinical trials primarily for solid tumors, including neuroblastoma, ovarian cancer, and small cell neuroendocrine prostate cancer[1][2]. Development is ongoing, with interest in improving efficacy and antigen sensitivity[3][6].

Other names

L1CAM CAR T-cellsL-1CAM CAR T-cellsL 1CAM CAR T-cellsL1CAM mutation specific T cellsL-1CAM mutation specific T cellsL 1CAM mutation specific T cellsCD171-directed CAR T-cellsCD-171-directed CAR T-cellsCD 171-directed CAR T-cells